

incomplete
Sub. F1

1. (Amended) A method of reducing [preventing] depletion in a mammal [an animal] of non-autologous hematopoietic cells comprising [decreasing] administering to the mammal an effective amount of an agent which selectively decreases the number of endogenous macrophages to a level effective to [substantially prevent] reduce depletion of the non-autologous hematopoietic cells.

F1

2. (Amended) The method according to claim 1 wherein the non-autologous hematopoietic cells are injected into the mammal [animal].

Sub. F2

3. (Amended) The method according to claim 1 wherein the ^{*non-autologous hematopoietic*} cells are made by hematopoietic tissue engrafted into the mammal [animal].

4. (Cancelled) The method according to claim 1 wherein the macrophages are decreased by administering to the animal an effective amount of an agent which decreases the level of endogenous macrophages.

F2

5. (Amended) The method according to claim [4] 1 wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

6. (Cancelled) The method according to claim 1 wherein the macrophages are decreased genetically.

7. (Amended) The method according to claim 1 wherein the mammal [animal] is immunocompromised.

F3

Sub. F3

8. (Amended) The method according to claim 7 wherein the mammal [animal] is immunocompromised due to infection with an immunodeficiency virus.

BEST AVAILABLE COPY

9. (Amended) The method according to claim 8 wherein the mammal [animal] is human and the virus is human immunodeficiency virus.

10. (Amended) The method according to claim 7 wherein the mammal [animal] is immunocompromised due to radiation therapy.

11. (Amended) The method according to claim 7 wherein the mammal [animal] is immunocompromised due to chemotherapy.

12. (Amended) The method according to claim 7 wherein the mammal [animal] is selected from the group consisting humans, mice, scid/scid mice, SCID-hu mice, and CID horses.

13. (Amended) The method according to claim 12 wherein the mammal [animal] is a SCID-hu Thy/Liv mouse.

14. (Amended) The method according to claim 7 wherein the mammal [animal] is transplanted with non-autologous hematopoietic tissue.

15. (Amended) The method according to claim 7 wherein the non-autologous hematopoietic cells are injected into the mammal [animal].

17. (Amended) The method according to claim 15 wherein the mammal [animal] is a human and the non-autologous hematopoietic cells are injected.

18. (Amended) A method of treating an immunocompromised mammal [animal] comprising administering to the animal an effective amount of non-autologous hematopoietic cells and [decreasing] administering to the mammal an effective amount of an agent which

BEST AVAILABLE COPY

Sub. F6
selectively decreases the number of endogenous macrophages to a level sufficient to reduce
[prevent substantial] depletion of the non-autologous hematopoietic cells.

F-4
19. (Amended) A non-human mammal comprising human hematopoietic cells wherein the mammal contains a decreased level of endogenous macrophages sufficient to reduce [prevent substantial] depletion of non-autologous hematopoietic cells, wherein the decreased level of endogenous macrophages is achieved by administering to the mammal an effective amount of an agent which selectively decreases the number of endogenous macrophages.

F-5
24. (Amended) A method of restoring hematopoietic cells to an immunocompromised human comprising the steps of administering an effective amount of human peripheral blood cells in conjunction with [decreasing] administering to the human an effective amount of an agent which selectively decreases the number of endogenous macrophages.

F-6
indefinite
31. (Twice Amended) A method of improving engraftment efficiency for transplantation of a population of non-autologous hematopoietic stem cells in a host mammal [animal] having an endogenous hematopoietic stem cell population, comprising the steps of ablating the endogenous hematopoietic stem cell population of the host mammal [animal] and transplanting the non-autologous hematopoietic stem cells into the host animal in conjunction with [decreasing] administering to the mammal an effective amount of an agent which selectively decreases the number of endogenous macrophages in the host mammal [animal].

F-7
32. (New) A method according to claim 18, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

33. (New) A method according to claim 19, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

BEST AVAILABLE COPY

34. (New) A method according to claim 24, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

35. (New) A method according to claim 31, wherein the agent is liposome-encapsulated dichloromethylene diphosphonate.

II. REMARKS

Status of the claims

Applicants' representative wish to thank the Examiner for the courtesy of a telephonic interview in which allowable claims were discussed.

Prior to this amendment, claims 1-31 were pending in this case. By virtue of this amendment, claims 1-3, 5 and 7-35 are pending in the case.

Generally, the claims are amended to define the invention more specifically and to correct errors pointed out by the Examiner or noted by the Applicants.

Applicant notes that the foregoing amendments to the claims are made solely to expedite allowance of the instant application, and do not constitute an acquiescence to any objection or rejection, or an abandonment or dedication of any subject matter. Applicant expressly reserves the right to claim any excluded subject matter in one or more continuing applications.

The amendments to the claims are supported by the specification and no new matter has been introduced. Entry of these amendments is respectfully requested. Reexamination and reconsideration of the claims, as amended, are respectfully requested.

III. CONCLUSION

In view of the amendments shown above, Applicants respectfully request that all outstanding rejections be withdrawn, and that the pending claims, as amended, be allowed.

BEST AVAILABLE COPY